ERG (TMPRSS2-ERG)Catalog number: ERG002-0.5
In prostate cancer, the ERG gene locus may undergo a chromosomal translocation with the androgen-regulated transmembrane protease serine 2 (TMPRSS2) gene, resulting in the expression of an TMPRSS2-ERG oncoprotein. The TMPRSS2-ERG fusion has been found to be the most common proto-oncogene present in prostate cancers, occurring in 50-70% of cases. Molecular methods (FISH, bDNA) have shown a strong correlation between TMRPSS2-ERG rearrangement status and ERG expression, as detected by IHC. ERG oncoprotein expression has been shown to be a highly specific marker for prostate cancer. Given the lack of ERG expression in a wide variety of normal epithelial tissues and tumors, and its robust presence in prostatic adenocarcinoma, detection of ERG by IHC is a valuable tool for diagnosing prostate cancer or determining prostatic origin. ERG is also highly expressed in vascular endothelial cells, making it a very specific marker for vascular tumors. Human ERG.
Immunogen: C-terminal synthetic peptide of human ERG
Purified antibody with 0.2% BSA and 15 mM sodium azide as preservative
Purification Method: Purified antibody with 0.2% BSA and 15 mM sodium azide as preservative
Secondary Reagents: Anti-rabbit IgG:Biotin conjugate (code no. ZU101) in conjunction with Streptavidin-HRPO (code no. ZU054)
Species Reactivity: Human, others not known
Incubation Time: 60 min at RT
Working Concentration: (liquid conc.) 1:50 - 1:100
Pre-Treatment: HIER (heat induced epitope retrieval)
Positive Control: ERG-positive prostate carcinoma
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, Suleman K, Varambally S, Brenner JC, MacDonald T, Srivastava A, Tewari AK, Sathyanarayana U, Nagy D, Pestano G, Kunju LP, Demichelis F, Chinnaiyan AM, Rubin MA. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia. 2010 Jul;12(7):590-598. 2. Chaux,A., Albadine,R., Toubaji,A., Hicks,J., Meeker,A., Platz,E.A et al. (2011) Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas, Am. J. Surg. Pathol. 35 (7), 1014-1020 PUBMED 21677539 3. Yaskiv,O., Zhang,X., Simmerman,K., Daly,T., He,H., Falzarano,S., Chen,L., Magi-Galluzzi,C. and Zhou,M. (2011) The utility of ERG/P63 double immunohistochemical staining in the diagnosis of limited cancer in prostate needle biopsies, Am. J. Surg. Pathol. 35 (7), 1062-1068 PUBMED 21623182 4. Miettinen,M., Wang,Z.F., Paetau,A., Tan,S.H., Dobi,A., Srivastava,S. and Sesterhenn,I. (2011) ERG transcription factor as an immunohistochemical marker for vascular endothelial tumors and prostatic carcinoma, Am. J. Surg. Pathol. 35 (3), 432-441 PUBMED 21317715 5. Queisser A., Hagedorn S.A., Braun M., Vogel W., Duensing S., Perner S. (2015) Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer. ModernPathology 28, 138–145.
Safety Datasheet(s) for this product:
$679.00Add To Cart